Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ARMGO Pharma, Inc. logo — First-in-Class Disease-Modifying Therapeutics in Cardiac and...

ARMGO Pharma, Inc.

First-in-Class Disease-Modifying Therapeutics in Cardiac and Skeletal Muscle Diseases

Founded 2006 United States United States 12 employees Series B Total: $36.00M Biotechnology, Health and Wellness +1

General Information

Company Name ARMGO Pharma, Inc.
Founded Year 2006
Location United States United States
Founders / Decision Makers
Team member
Employees 12
Industries Biotechnology, Health and Wellness, Platforms
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with ARMGO Pharma, Inc.. To contact ARMGO Pharma, Inc., visit armgo.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ARMGO Pharma, Inc. compare?

A PDF of ARMGO Pharma, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ARMGO Pharma, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ARMGO Pharma, Inc.

ARMGO Pharma, Inc. is a biopharmaceutical company that has been developing targeted small-molecule therapeutics to combat severe cardiac, skeletal muscular, and neurological disorders since 2004. The company's flagship products, rycals, act as calcium release channel stabilizers targeting the ryanodine receptor/calcium release channel on the sarcoplasmic/endoplasmic reticulum of cells. These small-molecule therapeutics have the potential to address a wide range of conditions including chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. In December 2021, ARMGO Pharma, Inc. secured a significant $35.00M Series B investment led by Kurma Partners, Pontifax, and Forbion. The company is headquartered in Tarrytown, New York, with an additional office in New York, New York. ARMGO Pharma, Inc.'s commitment to addressing unmet medical needs within the biotechnology industry, as well as its successful funding round, positions the company as a promising player in the development of novel therapeutics for a range of debilitating disorders.

Business keywords: Biopharmaceutical, Therapeutics, Small-molecule, Cardiac disorders, Muscular disorders, Neurological disorders, Rycals, Calcium release channel stabilizers, Ryanodine receptor, Chronic heart failure, Cardiac arrhythmias, Malignant hyperthermia, Diabetes, Chronic obstructive pulmonary disease, High blood pressure

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $35.00M 3
Kurma Partners Pontifax Forbion
Kurma Partners, Pontifax +1
20 Dec 2021
Seed Round $1.00M -
24 Aug 2011

ARMGO Pharma, Inc. Alternatives & Competitors

View All Alternatives
ARMGO Pharma, Inc. vs
Reservoir Neuroscience
Reservoir Neuroscience United States

Developing the world's first therapeutics to heal broken blood vessels in the brain

Venture round
3 employees
Biopharma, Biotechnology
ARMGO Pharma, Inc. vs
Nanna Therapeutics
Nanna Therapeutics United Kingdom

Disease-modifying Medicines

Grant
20 employees
AI, Biotechnology
ARMGO Pharma, Inc. vs
Abarceo Pharma AB
Abarceo Pharma AB Sweden

Developing the first disease modifying and durable treatment for type 2 and type 1 diabetes.

Venture round
9 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About ARMGO Pharma, Inc.

First-in-Class Disease-Modifying Therapeutics in Cardiac and Skeletal Muscle Diseases
ARMGO Pharma, Inc. was founded in 2006.
ARMGO Pharma, Inc. is headquartered in United States.
ARMGO Pharma, Inc. operates in Biotechnology, Health and Wellness and Platforms. Its work centres on Biopharmaceutical, Therapeutics, Small-molecule and Cardiac disorders.
ARMGO Pharma, Inc. has approximately 12 employees.
ARMGO Pharma, Inc. has completed 2 funding rounds, raising a total of $36.00M. The latest funding stage is Series B.
Top alternatives and competitors to ARMGO Pharma, Inc. include Reservoir Neuroscience, Nanna Therapeutics, Abarceo Pharma AB, Spinogenix, Inc., Biomea Fusion. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ARMGO Pharma, Inc. and Reservoir Neuroscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ARMGO Pharma, Inc., https://bouncewatch.com/company/armgopharmainc, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout